New marburg vaccine shows promise in early human trial
NCT ID NCT06265012
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a new vaccine called PHV01 against Marburg virus, a rare but severe disease. 36 healthy adults received either the vaccine or a placebo to check safety and immune response. The study aims to find a safe dose and see if the vaccine triggers antibodies against the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Marburg virus vaccine (PHV01)
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent Marburg virus disease, a rare but often fatal illness.
- What could go wrong
- This is an early Phase 1 trial with only 36 people, so results may not apply to larger populations. The vaccine may not produce a strong enough immune response or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel RCA
Hollywood, Florida, 33024, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.